Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazirsiran in AATD-associated liver disease (F1 fibrosis)
NCT06165341Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- Aug 2028
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 13
01
Overview
A Phase 3 trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Started Mar 2024; status: recruiting.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06165341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165341.